Form 4: Immunovant Director Atul Pande Sells Shares Under 10b5-1 Plan

Immunovant director Atul Pande sold 7,750 shares of common stock at a weighted average price of $28.54, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Atul Pande, a director at Immunovant, Inc., sold 7,750 shares of common stock on December 2, 2024.
• The shares were sold at a weighted average price of $28.54 per share.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 24, 2023.
• The purpose of the sale was to satisfy tax obligations related to the vesting of restricted stock units.
• The shares were sold in multiple transactions with prices ranging from $28.03 to $29.00 per share.
• Following the transaction, Atul Pande directly owns 86,663 shares of Immunovant common stock and indirectly owns 20,000 shares through a trust.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction by a company director under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction for a company director and is not unusual. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading.

Comparison to Industry Standards

• Sales by insiders under 10b5-1 plans are a common practice across the industry.
• The sale of 7,750 shares is not a significant amount compared to the total outstanding shares of Immunovant.
• Similar transactions are regularly reported by directors and officers of other publicly traded companies such as Regeneron, Amgen, and Biogen.

Stakeholder Impact

• The sale of shares by a director may have a minor impact on shareholder sentiment, but is unlikely to have a significant effect on the company's operations or value.

Key Dates

Keywords

Immunovant, Atul Pande, stock sale, Form 4, 10b5-1 plan, insider trading, share transaction, director